Clinical trial
A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT07830758 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- December 31, 2027
- Enrollment
- 90 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure with preserved ejection fraction (hfpef), mash - metabolic dysfunction-associated steatohepatitis